nct_id: NCT06695026
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2024-11-19'
study_start_date: '2024-12-18'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: RZ-001 Dose 2'
  - drug_name: 'Drug: RZ-001 Dose 3'
  - drug_name: 'Drug: RZ-001 Dose 1'
long_title: A Phase 1b/2a, Open-label, Multicenter, Randomized, Dose Escalation Study
  Evaluating the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir
  and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma
last_updated: '2025-07-29'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE1
principal_investigator: NA
principal_investigator_institution: Rznomics, Inc.
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 45
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- '* Adult males and females'
- '* Hepatocellular carcinoma diagnosis (BCLC stage B or C)'
- '* hTERT positive expression confirmed during the screening period'
- '* ECOG score of 0 or 1'
- '* Child-Pugh score of A'
- '* Life expectancy \>= 3 months'
- 'Exclude - Exclusion Criteria:'
- Exclude - * Moderate or severe ascites
- Exclude - * History of hepatic encephalopathy
- Exclude - * Carcinomas other than HCC
- Exclude - * Current or history of HIV positive
- Exclude - * Not suitable for inclusion judged by the investigator
short_title: A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in
  Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects
  With Hepatocellular Carcinoma
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Rznomics, Inc.
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: This study is to evaluate the safety, tolerability, efficacy and immunogenicity
  of RZ-001 in combination with Valganciclovir (VGCV) and Atezolizumab/Bevacizumab
  when given to subjects with human telomerase reverse transcriptase (hTERT)-positive
  HCC.
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Cohort 1
      arm_internal_id: 0
      arm_description: 'o Interventions:


        Drug: RZ-001 Dose 1'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: RZ-001 Dose 1'
        level_internal_id: 0
        level_suspended: N
    - arm_code: Cohort 2
      arm_internal_id: 1
      arm_description: 'o Interventions: Drug: RZ-001 Dose 2'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: RZ-001 Dose 2'
        level_internal_id: 0
        level_suspended: N
    - arm_code: Cohort 3
      arm_internal_id: 2
      arm_description: 'o Interventions: Drug: RZ-001 Dose 3'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: RZ-001 Dose 3'
        level_internal_id: 0
        level_suspended: N
    match:
    - and:
      - or:
        - clinical:
            oncotree_primary_diagnosis: Hepatocellular Carcinoma
        - clinical:
            oncotree_primary_diagnosis: Fibrolamellar Carcinoma
      - clinical:
          age_numerical: '>=18'
          disease_status:
          - Localized
          - Advanced
